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Summary SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide) is an anti-tumour agent that has a highly
selective toxicity to hypoxic cells. In this study we delineate the role of several different bioreductive enzymes
in the metabolism of SR 4233 by two tumour cell lines HT 1080 (human fibrosarcoma) and SCCVII (mouse
carcinoma). Enzyme kinetics demonstrates similar KM of HT 1080 and SCCVII cell sonicates and differing
Vmax. Among all cofactors tested, NADPH was the most important one in reducing SR 4233 by both tumour
cell sonicates. NADH was the second most important cofactor while hypoxanthine and N-methylnicotinamide
were less involved in the reduction of SR 4233. Carbon monoxide inhibited the reduction by about 60%
suggesting that cytochrome P-450 may play a major role in the reduction of SR 4233 under hypoxia in both
SCCVII and HT 1080 cells. DT diaphorase is also involved, particularly in HT 1080 cells, in this drug
reduction. The level of functional cytochrome P-450, cytochrome P-450 reductase activity and DT diaphorase
activity in both cell lines were assayed. These enzyme levels were all higher in SCCVII cells than in HT 1080
cells. This result correlated the higher V,,ax of SR 4233 reduction in SCCVII cells than in HT 1080 cells.
SR 4233 is presently in phase I clinical trials as a potential
anti-tumour agent. This drug has a highly selective toxicity to
a variety of hypoxic mammalian cell lines in vitro (Zeman et
al., 1986) and causes extensive tumour cell death in vivo when
combined with radiation (Zeman et al., 1988; Brown & Lem-
mon, 1990), or with agents that induce tumour hypoxia
(Brown, 1987; Sun & Brown, 1989). Previous studies in our
laboratory have proposed a metabolic pathway of SR 4233
under hypoxia showing that two major reduction products
are found, a two-electron reduction product SR 4317 and a
four-electron reduction product SR 4330 (Baker et al., 1988).
However since neither of these is toxic to either hypoxic or
aerobic cells, we have suggested that the toxic species is
probably the single electron reduction intermediate, neces-
sarily a free radical (Baker et al., 1988; Laderoute et al.,
1988; Zeman et al., 1986). Recent EPR studies have unequi-
vocally identified the production of a free radical from the
enzymatic reduction of SR 4233 under hypoxia (Lloyd et al.,
1991). This free radical intermediate is either back-oxidised
by molecular oxygen, in the presence of oxygen, to yield
superoxide and the parent drug or acquires a second electron,
in the absence of oxygen, to form the stable mono-N-oxide,
SR 4317. These divergent fates presumably confer the selec-
tivity of the hypoxic metabolism, and the abstraction of the
second electron from macromolecules, such as DNA, has
been suggested as the cause of the lethal damage to the cells
(Costa et al., 1989).
Several reductases may catalyse N-oxide reduction includ-
ing the microsomal enzymes NADPH:cytochrome P-450
reductase and cytochrome P-450, as well as the cytosolic
enzymes xanthine oxidase, aldehyde oxidase and DT dia-
phorase (Hewick, 1982; McLane et al., 1983). Studies by
Walton and Workman (1990) have shown that the major
reductase for SR 4233 reduction under hypoxic conditions in
mouse liver microsomes is cytochrome P-450. However, these
investigations do not necessarily mean that the same reduc-
tases will be the improtant ones in tumours. Recently, Riley
and Workman (1992) have found that SR 4233 may also be a
substrate for tumour DT-diaphorase. Since a major deter-
minant of tumour cell toxicity by SR 4233 is its rate of
bioreduction under hypoxia (Biedermann et al., 1991), it is
important to identify the major reductases in tumour cells.
Conceivably, levels of such enzymes in individual tumours
could then form a basis for predicting the antitumour efficacy
of SR4233 in humans.
We have used the tumour cell lines, SCCVII and HT 1080,
to examine the enzymology of the in vitro bioreduction of
SR 4233. The activity of relevant bioreductive enzymes in
these two cell lines were assayed. Our results suggested that
cytochrome P-450 may play an important role in reducing
SR 4233 under hypoxic conditions in SCCVII and HT 1080
cells.
Materials and methods
Chemicals
SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide) and its
reduction products, SR 4317 (3-amino-1,2,4-benzotriazine-l-
N-oxide) and SR 4330 (3-amino-1,2,4-benzotriazine), were
synthesized at SRI International, Menlo Park, CA, by Dr M.
Tracy under contract from the National Cancer Institute
(contract N01-CM-47611). Purified cytochrome P-450 reduc-
tase (P-450 reductase) from rat liver microsomes was pro-
vided by Dr Wold as described previously (Wolf & Oesch,
1983). The enzyme activity was 380.00 units ml' (one unit
being the amount of enzyme required to reduce 1 nmol cyto-
chrome c min-'). BCA (bicinchoninic acid) Protein Assay
Reagent was purchased from Pierce Inc., all other reagents
were purchased from Sigma Chemical Co., St. Louis, MO.
Cells
SCCVII cells, originally obtained from Dr K. Fu, Depart-
ment of Radiation Oncology, University of California, San
Francisco, were grown in Waymouth medium containing
15% foetal bovine serum. Details of the derivation and
handling of this cell line have been described previously
(Hirst et al., 1982). HT 1080 cells were obtained from the
American Type Culture Collection (ATCC) (Rockville,
Maryland) and grown in Alpha MEM medium (Grand Island
Biologicals Laboratories, Santa Clara, CA) containing 10%
foetal bovine serum (Flow Laboratories, Inc., Inglewood,
CA), both cell lines were grown in 126 mg ml-' penicllin, and
146 mg ml-' streptomycin.
Cellular sonicates
Cells were detached from culture flasks in late log phase of
growth by trypsinisation, washed once with potassium phos-
phate buffer (IOmM KH2PO4, 0.1 mM EDTA and 1.15% w/v
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KCl, pH 7.5), and resuspended at S x 107 cellml' in the
same buffer. Cell suspension was sonicated by four 10-second
bursts with a Sonifer Cell Disruptor (Model W185, Heat
System Ultrasonics, INC), at 50% of maximum intensity.
The cell suspension tubes were immersed in ice-water during
sonication.
Protein assay
Protein concentration was determined by BCA (Pierce
Chemical Co., IL) method (Redinbaugh & Turley, 1986) with
bovine serum albumin as the standard.
Enzyme assays
The functional state ofcytochrome P-450 in tumour cells was
detected by measuring a cytochrome P-450-dependent mon-
oxoygenase ethoxycourmarin 0-deethylase activity utilizing
the fluorometric determination of the 0-deethylation of 7-
ethoxycourmarin (Graeve et al., 1980; Rosenberg et al.,
1990). The reaction mixture, in a total volume of 2 ml,
contained MgCl2 (5 mM), BSA (1 mgml-'), NADPH (0.5
mM), NADH (0.5 mM) 80 mM of potassium phosphate buffer
(pH 7.4) and cell sonicates (2 to 10mgml-'). After a 5-min
preincubation at 37°C, the reaction was initiated by addition
of 20ftl of 7-ethoxycoumarin (0.431iM final) in methanol. The
mixture was incubated at 37°C for 20 min with shaking, and
the reaction was stopped by the addition of 250,sl of ice-cold
15% (w/v) trichloroacetic acid (TCA). For the sample
blanks, TCA was added prior to incubation. Following
extraction of incubates with 4 ml of chloroform, 2 ml of the
organic phase was extracted with 3 ml of 0.01 N NaOH, 1 M
NaCl solution. The concentration of 7-hydroxycoumarin in
the alkaline phase was determined fluorometrically by a Per-
kin Elmer LS3 fluorescence spectrophotometer (excitation at
368 nm and emission at 456 nm).
DT diaphorase activity was assayed as the method describ-
ed by Ernster (Ernster, 1967). 2,6-dichlorophenolindophenol
(DCPIP) was used as the electron acceptor while NADPH
was the electron donor.
NADPH-cytochrome P-450 reductase activity was measur-
ed as the rate of cytochrome c reduction as described by
Omura and Takesue (Omura & Takesue, 1970).
SR 4233 reduction assay
All hypoxic incubations were performed in a double side-
armed glass flask (Wheaton Jacketed Reaction Vessels) at
37°C with continuous stirring. The reaction mixture was
pregassed for 30 min by humidified 95% N2 and 5% C02,
and the gas flow continued throughout the experiment. The
enzymes were added 10 min before the initiation of the re-
action. The reaction was initiated by the addition of SR 4233
at the appropriate concentrations.
Each reaction mixture contained an enzyme source (0.1
to 1.0 mgml-' cell sonicates or purified P-450 reductase,
or purified xanthine oxidase), enzyme cofactors (0.9 mM
NADPH, 0.9 mM NADH, 1 mM hypoxanthine and 2.5 mM
N-methylnicotinamide for cell sonicates; NADPH for puri-
fied P-450 reductase; hypoxanthine for xanthine oxidase),
SR 4233 (60jM to 200ltM) and bicarbonate buffered salts
solution (BBS) buffer (129 mM NaCl, 26 mM NaHCO3, 5 mM
KCl, 3.4mM KH2PO4, 1.3 mM CaC12, 0.5 mM MgCl2, 0.4 mM
MgSO4 and 5 mM glucose, pH 7.4) in a final volume of
10 ml.
Immediately after SR 4233 addition and at each time
point, 1 ml of the mixture was removed and added to an
equal volume of ice-cold 50% methanol and 2% acetate,
centrifuged at 12,000g for 10min, and the supernatant was
taken for fluorescence measurement.
The fluorescence was monitored in a Perkin Elmer LS3
fluorescence spectrophotometer. The 1-oxide product SR
4317 is 60-fold more fluorescent at 416 nm excitation and
516 nm emission than is SR 4233, thus making detection of
SR 4317 possible even at l4M concentration. Inhibition by
oxygen or carbon monoxide was carried out by replacing the
nitrogen gas with humidified air with 5% CO2 or 99.5%
carbon monoxide (CO) respectively at the same flow rate.
The DT diaphorase inhibitor dicoumarol was added to give a
final concentration of 100tiM.
Results
Kinetics ofenzymic reactions
Figure 1 shows the Lineweaver-Burk plot of the kinetics of
reduction of SR 4233 to its 2-electron reduction product
SR 4317 by sonicates of SCCVII and HT 1080 cells. The
Michaelis constant, KM, of SCCVII and HT 1080 sonicates
were not significantly different (74.8 ± 11.1 t4M and 71.8 ±
11.4tIM respectively). Calculation of the maximal velocities,
Vmax, however, were different, with values of 1.6 ± 0.5 and
2.7 ± 0.2 nmol min-1 mg' protein for HT 1080 and SCCVII
sonicates respectively (mean ± s.e., n = 3).
Enzyme cofactor and inhibitor studies
Several enzymes known to be involved in the activation of
bioreductive drugs by single or double electron transfer could
reduce SR4233, including cytochrome P-450, xanthine oxi-
dase, aldehyde oxidase, NADPH P-450 reductase and DT-
diaphorase (Hewick, 1992; Rajagopalan, 1980; Walton &
Workman, 1990; Wolpert et al., 1973). In order to determine
which, if any, of these bioreductive enzymes were active in
reducing SR 4233 in the tumour cell homogenates we added
various cofactors listed below into the reaction mixtures. The
enzyme cofactors hypoxanthine and N-methylnicotinamide,
which are cofactors of xanthine oxidase and aldehyde oxi-
dase, did not show a significant degree of reduction (less than
10%) of SR 4233 under hypoxia. NADH, a cofactor of DT
diaphorase and many other NADH oxidoreductase enzymes,
contributed 30.9 ± 3.4% and 63.6 ± 3.2% (mean + s.e., n = 3)
of the reduction of SR 4233 under hypoxia of SCCVII and
HT 1080 sonicates respectively. NADPH, the cofactor of
cytochrome P-450, NADPH:P-450 reductase as well as DT
diaphorase and others, however, contributed 50.1 ± 1.6%
and 80.0 ± 6.2% of the reduction of SR 4233 by SCCVII and
HT 1080 sonicates respectively (Figure 2a and b). To deter-
mine which NADPH reductase is the major enzyme responsi-
ble for the reduction of SR 4233 in these two tumour cell
lines, we added dicoumarol, an inhibitor of DT diaphorase,
or carbon monoxide, an inhibitor of cytochrome P-450 into
the reaction mixtures. Figure 3 (a and b) shows that 100 11M
dicoumarol (at which concentration inhibits 90% of DT
diaphorase activity in reducing DCPIP) inhibited SR4233
metabolism in SCCVII and HT 1080 sonicates by 27.9 ±
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Figure 1 Double reciprocal plot showing KM and Vmax of
SR 4233 reduction by SCCVII and HT 1080 cell sonicates. Open
symbols are HT 1080 cell sonicates and closed symbols are
SCCVII cell sonicates. For the reaction conditions see Materials
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0.6% and 41.3 ± 2.6% respectively while carbon monoxide
(cO) produced a 68.6 ± 5.7% and 58.1 ± 3.7% (mean + s.e.,
n = 3) inhibition in SCCVII and HT 1080 sonicates respec-
tively.
Different enzyme levels in SCCVII and HT 1080 cells
1 Three NADPH enzyme activities in SCCVII and HT 1080
cells were determined by their standard assays. Table I shows
I- the rates of SR 4233 reduction, cytochrome P-450 levels (ex-
pressed as 7-ethoxycoumarin 0-deethylase activity), P-450
reductase activities (reduction of cytochrome c) and DT dia-
phorase activities (reduction of DCPIP) in SCCVII and HT 20 25 1080 cells. In SCCVII cells, the rate of SR 4317 formation
was about 1.7 fold higher than that in HT 1080 cells. The
b levels of the enzyme tested were all higher in SCCVII cells
than that in HT 1080 cells by the fact of 3.5 (cytochrome
P-450), 1.9 (P-450 reductae) and 2.2 (DT diaphorase).
1?/ SR 4233 reduction bypurified P-450 reductase
Figure 4 shows the rate of SR 4233 reduction by various
amount of purified P-450 reductase (0.5 unitsml- to 2.0
unitsml-'). The unit of this purified enzyme is defined in
Materials and methods.
30 35 40 Discussion
From previous studies, several mechanisms have been pro-
f various cofactors posed for the anaerobic reduction to produce free radicals
under hypoxi. [SR from various N-oxides (Bachur et al., 1978; Mason & Chig-
sonicates were 0.6 nell, 1982; McLane et al., 1983). In the present study we have
all cofactors; (0) shown that SR 4233 is reductively metabolised under hypoxic
Eonly; (*) 1 mM conditions to SR 4317 by the rodent and human tumour cell
Inicotinamide only. lines, SCCVII and HT 1080. In both cell lines the reduction
experiments. of SR 4233 was largely dependent upon NADPH (50% and
80% for SCCVII and HT 1080, respectively), a cofactor of
a cytochrome P-450, NADPH-P-450 reductase, DT diaphorase
and other enzymes. In the presence of NADPH, the reduc-
tion was inhibited more than 60% by a specific inhibitor of
cytochrome P-450, carbon monoxide, in both cell lines. This
suggests that cytochrome P-450 may play an important role
1.0 'in the reduction of SR 4233 in both tumour cell lines. About
30% and 66% of the reduction was dependent upon NADH
in SCCVII and HT 1080 cells, respectively. The inhibition
studies showed that this in part could be due to the action of
DT diaphorase. The other two reductase cofactors, hypoxan-
thine and N-methylnicotinamide, did not significantly contri-
bute to SR 4233 reduction in either cell lines. Therefore, we
conclude that cytochrome P-450 may play the major role in
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Figure 3 The effect of various inhibitors of NADPH reductases
on SR 4233 metabolism in hypoxic SCCVII (A) and HT 1080 (B)
sonicates. [SR 4233] = 60SAM, protein concentration of cell soni-
cates were 0.6 to 1.0mg ml, Symbols: (0) control; (0) 100 tuM
dicoumarol and (A) carbon monoxide. The results are the aver-
age of two or three experiments.
20
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Figure 4 SR 4233 reduction by purified P-450 reductase under
hypoxic conditions. Reaction mixture contained 200fM SR 4233,
NADPH regenerating system (0.75 mM NADP, 5 mM glucose
6-phosphate and 1.25 units ml glucose 6-phosphate dehydrogen-
ase) and 2.0 u (0), 1.0 u (A), 0.5 u (A) or 0 u (0) P-450
reductase in BBS buffer. See Materials and methods for other
conditions.
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Table I Rate of SR 4233 reduction, functional cytochrome P-450 level, P-450
reductase activity and DT diaphorase activity in SCCVII and HT 1080 cells
(mean±s.d., n = 3)
(nmolproductmin1' mg ' protein) Ratio
Enzyme activity SCCVII HT 1080 (SCCVII/HT 1080)
SR 4233 reduction 2.45±0.09 1.46±0.03 1.7
cytochrome P-450 4.06±0.58 x 10-3 1.15±0.28 x 10-3 3.5
P450 reductase 7.95±0.12 4.28±0.13 1.9
DT diaphorase 0.25±0.03 0.11 ±0.06 2.2
the reduction of SR 4233 in both tumour cell lines; while DT
diaphorase has a minor contribution to SR 4233 reduction by
SCCVII cells, but is the second most important enzyme in
reducing SR 4233 by HT 1080 cells.
Using mouse liver microsomes as the enzyme source, we
have also confirmed the results of Walton and colleagues
(Walton et al., 1989; Walton & Workman, 1990) that cyto-
chrome P-450 is the major reductase in the reduction of
SR 4233 based on the 60% to 80% inhibition of reduction by
the P-450 inhibitor, carbon monoxide. On the other hand,
however, Cahill and White (1990) and Lloyd et al. (1991)
found no inhibition of reduction of SR 4233 by carbon
monoxide using rat liver microsomes. Whether this disagree-
ment reflects a difference between mouse and human on the
one hand, and rat on the other, or a technical problem with
the gassing time of carbon monoxide is not clear at present.
SCCVII and HT 1080 cells demonstrated similar KM but
differing Vma. This is consistent with their different sensi-
tivities to killing by SR 4233 under hypoxia: SCCVII cells are
more sensitive than HT 1080 cells (Biedermann et al., 1991).
In fact, because of the close relationship between rates of
drug reduction by different cell types and the sensitivies of
these cells to killing by SR 4233 under hypoxia, the present
data suggest that an independent measurement of the levels
of the appropriate enzyme in a tumour might form the basis
of an assay to predict the sensitivity of the tumour to be
killed by SR 4233. Our data ofsuch enzyme levels in SCCVII
and HT 1080 cells correlated well with the rate of SR 4233
metabolism in these cell lines (Table I).
SR 4233 can be a substrate for a broad spectrum of reduc-
tases in vitro. For example, Laderoute et al. (1988) showed
that xanthine oxidase could reduce SR 4233 and produce
plasmid DNA breakage in vitro. Our data with tumour cells,
however, indicate that xanthine oxidase plays a little or no
role in the reduction of SR4233 by either of the cell lines
investigated.
A further complication is that the cellular reduction of
SR 4233 that is responsible for cell killing may result from a
relatively narrow spectrum of enzymes at crucial cellular
locations, such as the nuclear membrane. We have shown,
for example, that cell killing by SR 4233 under hypoxia is the
result of chromosome aberrations apparently produced by
enzyme activation very close to the chromosome (Wang et
al., 1992). Drug reduction in these regions may or may not
be produced by the same spectrum of enzymes responsible
for total cellular reduction.
Approximately 30-40% of SR 4233 metabolism, however,
is mediated by as yet unidentified enzymes. Although P-450
reductase could, in principle, catalyse the reduction of
SR 4233 directly or via reduction of cytochrome P-450 and
account for the remaining activity, without a specific inhib-
itor, it is difficult to decide what role P-450 reductase does
play.
In conclusion, we have shown that SR 4233 is reductively
metabolised to SR 4317 by the tumour cell lines, SCCVII and
HT 1080, under hypoxic conditions. Cytochrome P-450 may
play a major (greater than 60%) role in both cell lines. Also,
in agreement with Riley and Workman (1992), DT diaphor-
ase is the second most important enzyme in reducing
SR 4233, particularly in HT 1080 cells. Xanthine oxidase and
aldehyde oxidase play little or no role in drug reduction in
both cell lines.
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